Results 281 to 290 of about 137,002 (346)

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists.

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of ...
Sadiya S Khan, C. Ndumele, Dhruv S. Kazi
semanticscholar   +3 more sources

Glucagon-like peptide 1 receptor

AfCS-Nature Molecule Pages, 2005
D. Hoersch, J. Schrader, R. Goeke
semanticscholar   +2 more sources

Glucagon-like peptide-1 receptor

Current Biology
Michael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
M. Krashes
semanticscholar   +3 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source